Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.
Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma (MCL).
The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are approved for the treatment of patients with MCL who have received at least 1 prior line of therapy, says Martin.
However, there is little evidence to suggest if one agent should be selected over another based on efficacy or safety, Martin explains.
As such, a randomized phase 3 trial comparing these agents head-to-head is warranted, Martin concludes.